180 related articles for article (PubMed ID: 22967451)
1. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
[TBL] [Abstract][Full Text] [Related]
2. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
Piedbois P; Serin D; Priou F; Laplaige P; Greget S; Angellier E; Teissier E; Berdah JF; Fabbro M; Valenza B; Herait P; Jehl V; Buyse M
Ann Oncol; 2007 Jan; 18(1):52-57. PubMed ID: 17047001
[TBL] [Abstract][Full Text] [Related]
3. [Phase II study of docetaxel plus epirubicin versus docetaxel plus cisplatin as first-line chemotherapy for advanced breast cancer].
Wang YJ; Wu Q; Su FX; Zhou LZ; Ye ZB; Yang JQ; Ren H; Zhang J; Ding G; Fu Q; Wang N
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):541-4. PubMed ID: 19062725
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Hui R; Zhang M; Hao XM; Zhang J
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):871-4. PubMed ID: 18396651
[TBL] [Abstract][Full Text] [Related]
5. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
Rom J; von Minckwitz G; Eiermann W; Sievert M; Schlehe B; Marmé F; Schuetz F; Scharf A; Eichbaum M; Sinn HP; Kaufmann M; Sohn C; Schneeweiss A
Ann Oncol; 2008 Oct; 19(10):1698-705. PubMed ID: 18477581
[TBL] [Abstract][Full Text] [Related]
6. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.
Rais G; Raissouni S; Aitelhaj M; Rais F; Naciri S; Khoyaali S; Abahssain H; Bensouda Y; Khannoussi B; Mrabti H; Errihani H
BMC Womens Health; 2012 Oct; 12():35. PubMed ID: 23039971
[TBL] [Abstract][Full Text] [Related]
7. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
[TBL] [Abstract][Full Text] [Related]
8. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Ellis P; Barrett-Lee P; Johnson L; Cameron D; Wardley A; O'Reilly S; Verrill M; Smith I; Yarnold J; Coleman R; Earl H; Canney P; Twelves C; Poole C; Bloomfield D; Hopwood P; Johnston S; Dowsett M; Bartlett JM; Ellis I; Peckitt C; Hall E; Bliss JM; ;
Lancet; 2009 May; 373(9676):1681-92. PubMed ID: 19447249
[TBL] [Abstract][Full Text] [Related]
9. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
Mavroudis D; Saloustros E; Boukovinas I; Papakotoulas P; Kakolyris S; Ziras N; Christophylakis C; Kentepozidis N; Fountzilas G; Rigas G; Varthalitis I; Kalbakis K; Agelaki S; Hatzidaki D; Georgoulias V
Br J Cancer; 2017 Jul; 117(2):164-170. PubMed ID: 28641315
[TBL] [Abstract][Full Text] [Related]
10. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of neoadjuvant chemotherapy in breast cancer patients].
Zhang B; Zhang Q; Zhao L; Long F; Li S; Jiang DQ; Xu H
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):867-70. PubMed ID: 17416014
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Vici P; Brandi M; Giotta F; Foggi P; Schittulli F; Di Lauro L; Gebbia N; Massidda B; Filippelli G; Giannarelli D; Di Benedetto A; Mottolese M; Colucci G; Lopez M
Ann Oncol; 2012 May; 23(5):1121-1129. PubMed ID: 21965475
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
[TBL] [Abstract][Full Text] [Related]
15. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
Reitsamer R; Peintinger F; Prokop E; Hitzl W
Anticancer Drugs; 2005 Sep; 16(8):867-70. PubMed ID: 16096435
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer.
Hurley J; Reis I; Silva O; Gomez C; DeZarraga F; Velez P; Welsh C; Powell J; Doliny P
Clin Breast Cancer; 2005 Feb; 5(6):447-54. PubMed ID: 15748465
[TBL] [Abstract][Full Text] [Related]
17. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
[TBL] [Abstract][Full Text] [Related]
18. [The safety of docetaxel with cyclophosphamide (TC) therapy as adjuvant chemotherapy for Japanese women with operable breast cancer].
Tashiro H; Sagawa T; Okada K; Kurokawa T; Soga H; Watanabe R; Yasuoka Y; Honda K; Watanabe Y; Gangi J; Akehi S; Masuda J; Nomoto M;
Gan To Kagaku Ryoho; 2007 Mar; 34(3):393-6. PubMed ID: 17353630
[TBL] [Abstract][Full Text] [Related]
19. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.
Jones RL; Walsh G; Ashley S; Chua S; Agarwal R; O'Brien M; Johnston S; Smith IE
Br J Cancer; 2009 Jan; 100(2):305-10. PubMed ID: 19165198
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and toxicity of combination treatment with epirubicin (EPI) plus docetaxel (DOC) in advanced breast cancer].
Takahashi M; Watanabe K; Takahashi H; Taguchi K; Tamura M; Hata Y; Todo S
Gan To Kagaku Ryoho; 2006 Nov; 33(11):1583-7. PubMed ID: 17108723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
